Venlafaxine efficacy and tolerability in the treatment of post-stroke depression

Psychiatria Danubina

Volumn 19, Issue 1-2, 2007, Pages 56-60

  Kučukalić, Abdulah ^a   Bravo Mehmedbašić, Alma ^a   Kulenović, Alma Džubur ^a   Suljić Mehmedika, Enra ^a  

^a KLINICKI CENTAR UNIVERZITETA U SARAJEVU   (Bosnia and Herzegovina)

Author keywords

Efficacy; Post stroke depression; Safety; Venlafaxine

Indexed keywords

VENLAFAXINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; INFORMED CONSENT; MALE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; SYMPTOM;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CEREBRAL INFARCTION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERSONALITY ASSESSMENT; PERSONALITY INVENTORY; TREATMENT OUTCOME;

EID: 34447262852     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. American Psychiatric Association: Practice Guidelines for the Treatment of Patients with Major Depressive Disorder (revision); American Journal of Psychiatry (Supplement) 157:4, 2000.
2. Joseph S: Symptom-Focused Psychiatric Drug Therapy for Managed Care. The Hawort Medical Press, New York-London 1997.
3. Thase ME et al: Venlafaxine and treatment - resistant depression. Depress Anxiety. 2000; 12 Suppl 1:55-62.
4. Claude de Montigny et al: Venlafaxine in Treatment-Resistant Major Depression: A Canadian Multicenter, Open-Label Trial. Journal of Clinical Psychopharmacology 1999; 19: 401-406.
5. Richard L. Rudolph, MD, Richard Entsuah, PhD: A Meta-Analysis of the Effects of Venlafaxine on Anxiety Associated With Depression. Journal of Clinical Psychopharmacology;1998; 18:212-221.
6. Rudolph RL, Derivan AT: The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database. Journal of Clinical Psychopharmacology 1996; 16(3 Suppl 2): 54S-59S; discussion 59S-61S. Review.